Trials / Unknown
UnknownNCT04866381
An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-6390 | SHR-6390 |
| DRUG | SHR-6390 + Camrelizumab (SHR-1210) | SHR-6390 combined with Camrelizumab (SHR-1210) |
| DRUG | Camrelizumab (SHR-1210) + SHR-1020 | Camrelizumab (SHR-1210) combined with SHR-1020 |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2023-04-01
- Completion
- 2023-04-01
- First posted
- 2021-04-29
- Last updated
- 2021-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04866381. Inclusion in this directory is not an endorsement.